GENMAB Aktie

>GENMAB Aktienkurs

234.5 EUR -0.1% (TradegateBSX)

Ask: 239 EUR / 25 Stück

Bid: 236 EUR / 25 Stück

Tagesumsatz: 191 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

GENMAB Aktie über LYNX handeln

Intraday

1 Jahr

>GENMAB Performance

1 Woche: +3,5%

1 Monat: -1,0%

3 Monate: -12,6%

6 Monate: -17,8%

1 Jahr: +35,2%

laufendes Jahr: -14,1%

>GENMAB Aktie

Name:

GENMAB AS DK 1

Land:

Dänemark

Sektor:

Gesundheit

ISIN/ Wkn:

DK0010272202 / 565131

Symbol/ Ticker:

GE9 (Frankfurt)

Kürzel:

FRA:GE9, ETR:GE9, GE9:GR

Index:

Webseite:

https://www.genmab.com/

Profil:

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, specializing in the discovery and development of antibody-based therapeutics primarily for cancer and other serious diseases. Founded in 1998, it focuses on innovative human ..
>Volltext..

Marktkapitalisierung:

14463.83 Mio. EUR

Unternehmenswert:

17615.13 Mio. EUR

Umsatz:

3326.49 Mio. EUR

EBITDA:

1177.46 Mio. EUR

Nettogewinn:

863.66 Mio. EUR

Gewinn je Aktie:

13.94 EUR

Schulden:

4690.38 Mio. EUR

Liquide Mittel:

1482.49 Mio. EUR

Operativer Cashflow:

1066.06 Mio. EUR

Bargeldquote:

1.2

Umsatzwachstum:

13.6%

Gewinnwachstum:

-19.06%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

GENMAB

Letzte Datenerhebung:

06.04.26

>GENMAB Kennzahlen

Aktien/ Unternehmen:

Aktien: 61.63 Mio. St.

Frei handelbar: 94.84%

Leerverk. Aktien: -

Rückkaufquote: 2.53%

Mitarbeiter: 3029

Umsatz/Mitarb.: 1.1 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 35.51%

Bewertung:

KGV: 17.32

KGV lG: 22.11

KUV: 4.8

KBV: 2.92

PEG-Ratio: -

EV/EBITDA: 14.96

Rentabilität:

Bruttomarge: 93.61%

Gewinnmarge: 25.96%

Operative Marge: 33.48%

Managementeffizenz:

Gesamtkaprendite: 9.95%

Eigenkaprendite: 17.2%

>GENMAB Peer Group

Gesundheit, Multiple Sklerose- Behandlung, Neurologische- & psychische Behandlung/ Medizin, Antikörper- Behandlung, Onkologie/ Krebs- Behandlung

>GENMAB Chart & Kurs - Tradegate

>GENMAB News

01.04.26 - 21:21	Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons (GlobeNewswire EN)
	Company Announcement...

27.03.26 - 13:06

Here Are Friday′s Top Wall Street Analyst Research Calls: Brown-Forman, Chord Energy, Emerson Electric, FuboTV, Genmab, Honeywell, Knight-Swift, Wix.Com, and More (24/7 Wall St.)

Pre-Market Stock Futures: Futures are trading lower as we prepare to end another up-and-down week, and, as we mentioned before, it all depends on the status of the war with Iran and the price of oil on any given day. Those two items have dictated the direction of stocks, bonds, precious metals, and crypto since ... Here Are Friday's Top Wall Street Analyst Research Calls: Brown-Forman, Chord Energy, Emerson Electric, FuboTV, Genmab, Honeywell, Knight-Swift, Wix.Com, and More The post Here Are Friday's Top Wall Street Analyst Research Calls: Brown-Forman, Chord Energy, Emerson Electric, FuboTV, Genmab, Honeywell, Knight-Swift, Wix.Com, and More appeared first on 24/7 Wall St.....

19.03.26 - 19:24

Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees in Genmab (GlobeNewswire EN)

Company AnnouncementCOPENHAGEN, Denmark; March 19, 2026 – Genmab A/S (Nasdaq: GMAB) Following Genmab A/S' Annual General Meeting held on March 19, 2026, the Company's Board of Directors met to constitute itself. Ms. Deirdre P. Connelly was appointed Chair and Ms. Pernille Erenbjerg was appointed Deputy Chair. It was decided to grant 5,213 restricted stock units and 4,485 warrants to the employees of the Company and the Company's subsidiaries.Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 1,645.00.The restricted stock units will vest on the first banking day of the month following a period of three years from the date of grant. Furthermore, the restricted stock units are subject to vesting conditions set out in the restricted stock unit program adopted by the Bo...

19.03.26 - 15:09	Passing of Genmab A/S′ Annual General Meeting (GlobeNewswire EN)
	Company Announcement...

02.03.26 - 21:00	Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons (GlobeNewswire EN)
	Company Announcement...

27.02.26 - 21:27	Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons (GlobeNewswire EN)
	Company Announcement...

27.02.26 - 21:24	Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab (GlobeNewswire EN)
	Company Announcement...

25.02.26 - 16:30	Genmab to Participate in Upcoming Investor Conferences (GlobeNewswire EN)
	Media ReleaseCOPENHAGEN, Denmark; February 25, 2026Genmab A/S (Nasdaq: GMAB) announced today that members of its Executive Committee will participate in fireside chats at the following investor conferences in March 2026: ...

24.02.26 - 21:24	Capital Increase in Genmab as a Result of Employee Warrant Exercise (GlobeNewswire EN)
	Company Announcement...

20.02.26 - 16:09	Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons (GlobeNewswire EN)
	Company Announcement...

18.02.26 - 15:12	Notice to Convene the Annual General Meeting of Genmab A/S (GlobeNewswire EN)
	Company Announcement...

18.02.26 - 13:18	Genmab drops 5% as mixed Epkinly data overshadows solid FY25 beat (Investing.com)
	Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

18.02.26 - 05:57	Genmab GAAP EPS of $15.37, revenue of $3.72B misses by $50M; initiates FY26 outlook (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

17.02.26 - 21:18	Genmab Announces Initiation of Share Buy-Back Program (GlobeNewswire EN)
	Company Announcement...

17.02.26 - 19:42	Earnings Call: Genmab verfehlt Gewinnprognose für Q4 2025, Aktie legt dennoch zu (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

17.02.26 - 18:42	Genmab Sees FY26 Revenue Of Up To $4.4 Bln (AFX)
	WASHINGTON (dpa-AFX) - Genmab A/S (GMAB) published its 2025 annual report and projected higher revenue for 2026, supported by royalty growth and strong product sales. The biotechnology company exp......

17.02.26 - 18:12	Genmab A/S Full Year Profit Drops (AFX)
	BRUSSELS (dpa-AFX) - Genmab A/S (GMAB) released earnings for full year that Dropped, from the same period last yearThe company's bottom line totaled $963 million, or $15.37 per share. This compare......

17.02.26 - 17:27	Genmab Files Annual Report with the U.S. Securities and Exchange Commission (GlobeNewswire EN)
	Media ReleaseCOPENHAGEN, Denmark; February 17, 2026...

17.02.26 - 17:03	Genmab Publishes 2025 Annual Report (GlobeNewswire EN)
	Company Announcement...

29.01.26 - 18:54	Grant of Restricted Stock Units and Warrants to Employees in Genmab (GlobeNewswire EN)
	Company Announcement...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Das sind halt die Freuden eines Preisministers, wenn ab und zu nicht alles teurer wird. - Dr. Josef Staribacher

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram